Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
NPACE Live Virtual Pre
Which of the following GLP-1 RA–based therapies has demonstrated statistically significant reductions in MACE in both injectable and oral forms, compared to placebo, in CV outcomes trials?
[ Required ]
Tirzepatide
Semaglutide
Orforglipron
Cagrilintide / semaglutide
Retatrutide
Which one of the following best describes the investigational GLP-1–based therapy cagrilintide / semaglutide?
[ Required ]
It targets GLP-1 and amylin receptors studied, in the REIMAGINE 3 trial
It targets GLP-1/GIP/glucagon receptors studied, in the TRANSCEND-T2D-1 trial
It is an oral non-peptide GLP-1 RA, studied in the ACHIEVE-1 trial
It targets GLP-1 and glucagon receptors, studied in the DREAMS-2 trial
It is a higher-dose semaglutide formulation, studied in STEP UP T2D
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
Submit